RE: ENDO IR response
yes, it looks like another refractory but patient entry conditions are much less restrictive than Phase IIIa, so data are not really adding to the 105. This is different.
Again, how can you get safety data from a second "double blind" Phase III without unblinding everything before the trial is over ?